哌柏西利在伴或不伴内脏转移的晚期乳腺癌患者管理中的临床考量
本文评估哌柏西利联合内分泌治疗在激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌伴或不伴内脏转移患者中的疗效与安全性。基于PALOMA-3和PALOMA-2研究的事后分析显示,哌柏西利联合内分泌治疗可延长内脏转移患者的无进展生存期、提高客观缓解率,并延迟既往治疗患者的生活质量恶化。
要点
- 内脏转移患者中,哌柏西利联合内分泌治疗较对照组显著延长无进展生存期并提高客观缓解率。
- 既往内分泌治疗耐药且伴内脏转移者,哌柏西利联合氟维司群延迟生活质量恶化。
- 晚期一线内分泌治疗初治的内脏转移患者,哌柏西利联合来曲唑维持患者报告生活质量。
核心结论
- 哌柏西利联合内分泌治疗延长内脏转移患者的无进展生存期并提高客观缓解率。
- 在既往因晚期乳腺癌治疗的患者中,哌柏西利联合内分泌治疗延迟生活质量恶化。
- 对适合内分泌治疗的内脏转移患者,哌柏西利联合内分泌治疗是标准治疗选择。
研究设计与样本
- 基于PALOMA-3(N=521)和PALOMA-2(N=666)两项随机对照研究的事后分析。
- PALOMA-3入组既往内分泌治疗后进展的绝经前和绝经后女性,按2:1随机接受氟维司群联合哌柏西利或安慰剂。
- PALOMA-2入组晚期乳腺癌未经治疗的绝经后女性,按2:1随机接受来曲唑联合哌柏西利或安慰剂。
- 按既往治疗和内脏受累情况评估无进展生存期、安全性和患者报告生活质量。
主要发现
- PALOMA-3中既往内分泌耐药患者内脏转移发生率为58.3%,PALOMA-2中晚期内分泌初治患者为48.6%。
- 既往内分泌耐药且伴内脏转移者,哌柏西利联合氟维司群中位无进展生存期9.2个月 vs 安慰剂联合氟维司群3.4个月(HR 0.47;95%CI 0.35-0.61)。
- 上述人群客观缓解率28.0% vs 6.7%;非内脏转移者中位无进展生存期16.6 vs 7.3个月(HR 0.53;95%CI 0.36-0.77)。
- 晚期内分泌初治且伴内脏转移者,哌柏西利联合来曲唑中位无进展生存期19.3个月 vs 安慰剂联合来曲唑12.9个月(HR 0.63;95%CI 0.47-0.85),客观缓解率55.1% vs 40.0%。
- 上述初治非内脏转移者中位无进展生存期未达到 vs 16.8个月(HR 0.50;95%CI 0.36-0.70)。
关键数值与推荐
- PALOMA-3:既往内分泌耐药且伴内脏转移者,哌柏西利联合氟维司群中位无进展生存期9.2个月 vs 3.4个月(HR 0.47;95%CI 0.35-0.61)。
- PALOMA-3:既往内分泌耐药且伴内脏转移者,客观缓解率28.0% vs 6.7%。
- PALOMA-3:既往内分泌耐药且非内脏转移者,中位无进展生存期16.6 vs 7.3个月(HR 0.53;95%CI 0.36-0.77)。
- PALOMA-2:晚期内分泌初治且伴内脏转移者,中位无进展生存期19.3个月 vs 12.9个月(HR 0.63;95%CI 0.47-0.85),客观缓解率55.1% vs 40.0%。
- PALOMA-2:晚期内分泌初治且非内脏转移者,中位无进展生存期未达到 vs 16.8个月(HR 0.50;95%CI 0.36-0.70)。
临床怎么用
- 对激素受体阳性/HER2阴性晚期乳腺癌伴内脏转移且适合内分泌治疗者,可考虑哌柏西利联合内分泌治疗。
- 既往内分泌耐药患者中,哌柏西利联合氟维司群可延长无进展生存期并延迟生活质量恶化。
- 晚期内分泌初治患者中,哌柏西利联合来曲唑可延长无进展生存期并维持患者报告生活质量。
局限性
- 本文为基于PALOMA-3和PALOMA-2的事后分析,内脏转移亚组结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases. PATIENTS AND METHODS: Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N = 521) and postmenopausal women untreated for ABC (PALOMA-2; N = 666) were randomized 2 : 1 to ET (fulvestrant or letrozole, respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were evaluated by prior treatment and visceral involvement. RESULTS: Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was 9.2 months with palbociclib plus fulvestrant versus 3.4 months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.35-0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with nonvisceral metastases, mPFS was 16.6 versus 7.3 months, HR 0.53; 95% CI 0.36-0.77. In patients with visceral disease and naive to ET in the advanced disease setting, mPFS was 19.3 months with palbociclib plus letrozole versus 12.9 months with placebo plus letrozole (HR 0.63; 95% CI 0.47-0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with palbociclib plus letrozole versus 16.8 months with placebo plus letrozole (HR 0.50; 95% CI 0.36-0.70). In patients with prior resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based therapy for ABC. CONCLUSIONS: Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral metastases amenable to endocrine-based therapy. CLINICAL TRIAL REGISTRATION: NCT01942135, NCT01740427.
引用
- Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018. PMID: 29342248. doi:10.1093/annonc/mdx797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。